These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24668702)

  • 21. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
    Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
    Vitale C; Marazzi G; Iellamo F; Spoletini I; Dall'Armi V; Fini M; Volterrani M
    Int J Cardiol; 2012 Mar; 155(2):279-84. PubMed ID: 22078979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.
    Gaudio C; Ferri FM; Giovannini M; Pannarale G; Puddu PE; Vittore A; Fera MS; Vizza CD; Fedele F
    J Cardiovasc Pharmacol; 2003 Nov; 42(5):622-8. PubMed ID: 14576510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D; Malmqvist K; Held C; Kahan T
    J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure.
    Karabacak M; Dogan A; Tayyar S; Bas HA
    Kardiol Pol; 2015; 73(3):201-6. PubMed ID: 25299401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy.
    Hallberg P; Lind L; Michaëlsson K; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Liljedahl U; Syvänen AC; Melhus H
    BMC Cardiovasc Disord; 2003 Sep; 3():11. PubMed ID: 13678427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients.
    Park CG; Ahn JC; Hong SJ; Kim EJ; Lee SJ; Park SM; Seo HS; Oh DJ
    Korean J Intern Med; 2006 Jun; 21(2):103-8. PubMed ID: 16913439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
    Erdoğan O; Ertem B; Altun A
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):310-3. PubMed ID: 21543293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
    Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
    J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network).
    Lønnebakken MT; Izzo R; Mancusi C; Gerdts E; Losi MA; Canciello G; Giugliano G; De Luca N; Trimarco B; de Simone G
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28275070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking.
    Vyssoulis GP; Marinakis AG; Aznaouridis KA; Karpanou EA; Arapogianni AN; Cokkinos DV; Stefanadis CI
    Am J Hypertens; 2004 Jul; 17(7):582-9. PubMed ID: 15233977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of blood pressure control in left ventricular mass regression.
    Miller AB; Reichek N; St John Sutton M; Iyengar M; Henderson LS; Tarka EA; Bakris GL
    J Am Soc Hypertens; 2010; 4(6):302-10. PubMed ID: 20980215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Realities of newer beta-blockers for the management of hypertension.
    Manrique C; Giles TD; Ferdinand KC; Sowers JR
    J Clin Hypertens (Greenwich); 2009 Jul; 11(7):369-75. PubMed ID: 19583633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study.
    Patrianakos AP; Parthenakis FI; Mavrakis HE; Diakakis GF; Chlouverakis GI; Vardas PE
    Am Heart J; 2005 Nov; 150(5):985. PubMed ID: 16290981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.
    Liljedahl U; Kahan T; Malmqvist K; Melhus H; Syvänen AC; Lind L; Kurland L
    J Hypertens; 2004 Dec; 22(12):2321-8. PubMed ID: 15614026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
    Bakris GL; Tarka EA; Waterhouse B; Goulding MR; Madan A; Anderson KM; St John Sutton M; Miller AB; Reichek N
    Am J Cardiol; 2006 Oct; 98(7A):46L-52L. PubMed ID: 17023232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction.
    Ozaydin M; Yucel H; Kocyigit S; Adali MK; Aksoy F; Kahraman F; Uysal BA; Erdogan D; Varol E; Dogan A
    Med Princ Pract; 2016; 25(4):316-22. PubMed ID: 27164841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.